Medication-Related Impairment of Fracture Healing: Mechanisms, Clinical Implications, and Management

Abstract

Medication-related impairment of fracture healing is an increasingly recognized complication in the management of patients with fractures. With the widespread use of various pharmacological agents in the general population, clinicians must remain vigilant regarding the effects of commonly prescribed medications—including corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anticoagulants, and certain chemotherapeutic agents—on bone repair. This comprehensive review synthesizes current evidence on epidemiology, pathophysiology, clinical features, diagnostic strategies, and management approaches for medication-induced delayed bone healing. The article further explores recent advances, emerging therapies, and contemporary guideline recommendations to aid healthcare professionals in optimizing patient outcomes.

Introduction

Fracture healing is a complex physiological process that can be adversely affected by systemic and local factors, including pharmacological therapies. As the prevalence of chronic diseases rises, the use of medications that may interfere with bone regeneration has become increasingly common. Understanding the mechanisms by which these drugs impair bone healing, recognizing at-risk populations, and employing evidence-based management strategies are essential for orthopedic surgeons, rheumatologists, and primary care providers. This review aims to provide clinicians with a critical appraisal of the literature, practical insights, and up-to-date recommendations for managing medication-related impairment of fracture healing.

Epidemiology / Disease Burden

The global burden of fractures is substantial, particularly among the elderly, with millions of fractures occurring annually. Epidemiological studies estimate that up to 10% of fractures may exhibit delayed union or nonunion, with medication use contributing significantly to these rates. Specifically, chronic corticosteroid therapy is associated with a 2–3-fold increased risk of impaired healing, while NSAID exposure, especially in the peri-fracture period, has been linked to higher rates of delayed union in both animal and human studies. Antiresorptive agents, such as bisphosphonates, though beneficial for osteoporosis, may paradoxically impair microdamage repair and contribute to atypical femoral fractures. The prevalence of medication-related fracture healing impairment is underreported, as recognition often requires high clinical suspicion and longitudinal follow-up.

Pathophysiology

Bone healing proceeds through a sequence of inflammatory, reparative, and remodeling phases. Medications can disrupt these stages via distinct mechanisms. Glucocorticoids suppress osteoblast differentiation, promote osteocyte apoptosis, and inhibit angiogenesis, all of which are vital for callus formation. NSAIDs, by inhibiting cyclooxygenase enzymes, reduce prostaglandin synthesis, impairing the initial inflammatory response and subsequent osteogenesis. Anticoagulants, particularly low molecular weight heparins, may interfere with bone matrix formation and vascularization. Chemotherapeutic agents and antiretrovirals can induce direct cytotoxic effects on osteoprogenitor cells. Understanding these mechanisms provides a rational basis for modifying pharmacotherapy in at-risk patients.

Risk Factors

Risk factors for medication-related impairment of fracture healing include advanced age, prolonged or high-dose medication use, polypharmacy, comorbidities such as diabetes or renal insufficiency, and poor nutritional status. Patients with autoimmune diseases often require chronic immunosuppression, further compounding risk. Genetic factors influencing drug metabolism and bone turnover may also play a role, as evidenced by variable responses to corticosteroids and NSAIDs among individuals. Early identification of these risk factors can facilitate tailored management and monitoring strategies.

Clinical Features

The hallmark of impaired fracture healing is persistent pain and functional limitation beyond the expected recovery period. Radiographically, delayed union or nonunion is characterized by absence of bridging callus, fracture line visibility, and lack of progressive consolidation over time. Physical examination may reveal local tenderness, swelling, and abnormal mobility. Clinical vigilance is warranted in patients receiving medications known to impair bone healing, particularly in the presence of risk factors or atypical fracture sites.

Diagnosis

Diagnosis is primarily clinical, supported by imaging modalities such as serial radiographs, computed tomography (CT), and, in select cases, magnetic resonance imaging (MRI) to assess callus formation and vascularity. Laboratory evaluation may include markers of bone turnover and inflammatory parameters, though these are not diagnostic. A thorough medication history is essential, as is assessment for alternative causes of impaired healing such as infection or metabolic bone disease. Multidisciplinary evaluation involving orthopedic, pharmacy, and specialty care is often required.

Treatment & Management

Management centers on modifying or discontinuing offending medications where feasible, optimizing comorbid conditions, and employing adjunctive therapies to promote healing. Short-term NSAID use may be permitted for analgesia, but prolonged administration should be avoided. Corticosteroids should be used at the lowest effective dose, and consideration given to bone-sparing alternatives or prophylactic measures such as calcium and vitamin D supplementation. Surgical intervention, including bone grafting or use of bone stimulators, may be indicated in cases of established nonunion. Patient education and close follow-up are critical to monitor progress and adjust therapy as needed.

Recent Advances / Emerging Therapies

Recent advances include the use of biological agents such as bone morphogenetic proteins (BMPs), platelet-rich plasma (PRP), and parathyroid hormone analogs to enhance bone regeneration in compromised patients. Low-intensity pulsed ultrasound (LIPUS) and extracorporeal shock wave therapy (ESWT) have shown promise in accelerating healing, particularly in high-risk populations. Pharmacogenomic approaches may enable individualized risk assessment and drug selection in the future. Ongoing clinical trials continue to investigate novel strategies to mitigate medication-induced bone healing impairment.

Guideline Recommendations

Contemporary guidelines emphasize the importance of minimizing exposure to medications known to impair fracture healing, especially during the acute post-injury phase. The American Academy of Orthopaedic Surgeons (AAOS) and international consensus statements recommend multidisciplinary medication review, judicious use of NSAIDs, and proactive management of osteoporosis. For patients requiring long-term corticosteroid therapy, concurrent use of bone-protective agents is advised. Clinical decision-making should be individualized, balancing the risks and benefits of essential medications against the potential for impaired healing.

Conclusion

Medication-related impairment of fracture healing represents a significant clinical challenge, with implications for patient outcomes, healthcare costs, and quality of life. Recognizing at-risk individuals, understanding mechanistic underpinnings, and implementing evidence-based management are crucial for optimizing bone repair in the context of necessary pharmacotherapy. Continued research and education are vital to refine therapeutic strategies and improve prognoses for affected patients.